Adam Smith, MD
Pulmonary Disease · Burlington, MANPI 1962734368
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $206,447 of the $296,148 with a category attached, or 69.7%. 26 manufacturers reported payments, led by GSK at 40.5% of the total. Reporting peaked in 2019 at $108,868 and has fallen 72.3% since, to $30,160 in 2025. Among pulmonary disease clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 680 payments — averaging $435.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$120K
- AstraZeneca$73K
- Boehringer Ingelheim$29K
- Regeneron Healthcare Solutions, Inc.$25K
- Insmed, Inc.$15K
- Regeneron$7K
- plus $28K from 20 others
What the payments were for
- Consulting fees$47,63416%
- Speaking & faculty fees$206,44770%
- Travel & lodging$27,2559%
- Food & beverage$14,7145%
- Education$980%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 180 | $119,815 |
| AstraZeneca | 257 | $73,142 |
| Boehringer Ingelheim | 63 | $28,823 |
| Regeneron Healthcare Solutions, Inc. | 40 | $24,740 |
| Insmed, Inc. | 21 | $14,730 |
| Regeneron | 12 | $6,538 |
| Novartis | 6 | $5,707 |
| Verona Pharma, Inc. | 11 | $5,124 |
| Mylan Specialty L.p. | 9 | $3,769 |
| Noah Medical Corporation | 8 | $3,261 |
| Roche Products Limited | 3 | $2,751 |
| Gyrus ACMI, Inc. | 3 | $2,237 |
| Radiometer America, Inc | 1 | $1,950 |
| BD | 1 | $850 |
| Amgen | 32 | $767 |
| Ambu A/s | 1 | $750 |
| Baxter Healthcare | 1 | $300 |
| United Therapeutics Corporation | 7 | $202 |
| Sanofi | 8 | $192 |
| Philips North America LLC | 5 | $184 |
| Galvanize Therapeutics, Inc | 1 | $79 |
| Genentech USA, Inc. | 4 | $69 |
| Astellas Pharma US Inc | 2 | $51 |
| Tactile Systems Technology Inc | 1 | $50 |
| Sunovion Pharmaceuticals Inc. | 2 | $46 |
| Pfizer | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$87,668
- FASENRA$63,238
- DUPIXENT$29,868
- NUCALA$12,715
- ANORO$11,711
- XOLAIR$5,645
- Ohtuvayre$4,800
- Yupelri$3,698
- BREZTRI$2,807
- TCM CombiM module$1,950
- MEDICAL CONTROL UNIT FOR ENDOSURGERY UCES-4$1,412
- ANORO ELLIPTA$1,200
- IPS - Liquid Premix$300
- GILENYA$240
- AIRSUPRA$109
How this compares
$296,148 in reported general payments places this provider in the 95th percentile of 482 pulmonary disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 49 | $629,610 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 584 | $432,314 |
| TezspireTezepelumab-Ekko | 39 | $178,999 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 253 | $159,523 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 244 | $136,477 |
| Pirfenidone | 15 | $96,739 |
| Fasenra PenBenralizumab | 17 | $95,430 |
| Dupixent SyringeDupilumab | 17 | $72,271 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 111 | $64,211 |
| Breo ElliptaFluticasone/Vilanterol | 119 | $56,961 |
| Dupixent PenDupilumab | 11 | $41,162 |
| Spiriva RespimatTiotropium Bromide | 66 | $37,999 |
| SymbicortBudesonide/Formoterol Fumarate | 118 | $33,606 |
| Advair HfaFluticasone Propion/Salmeterol | 61 | $30,083 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 108 | $27,829 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat | $28,823 | $753,814262 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $119,815 | $658,342999 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $73,142 | $372,128410 claims |
| PfizerEliquis | $22 | $9,43716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 482 pulmonary disease providers in Massachusetts.
Other pulmonary disease in Burlington
- Carla LambBurlington$27K
- Cyrus KholdaniBurlington$16K
- Yaron GoldmanWorcester$843K
- Sarah GrantBrookline$678K
- Erik FolchBoston$543K
- Bartolome CelliBoston$536K
- Fernando MartinezWorcester$375K
- Ana CojocaruFall River$364K
- Adnan MajidBoston$351K
- Nicholas HillBoston$293K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.